Biosimilars
•15 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (15)
%
| Company | Market Cap | Price |
|---|---|---|
|
Humira biosimilar erosion is referenced as a driver of AbbVie’s post-Humira strategy, aligning with biosimilars.
|
$431.71B |
$236.56
-1.80%
|
|
Abbott has a biosimilars pipeline launching in 2026, aligning with the biosimilars investable theme.
|
$230.52B |
$132.57
-1.21%
|
|
Amgen has a leading biosimilars franchise with PAVBLU, WEZLANA, BEKEMV and ongoing biosimilar launches.
|
$156.00B |
$290.13
-2.04%
|
|
Cordavis biosimilars illustrate CVS's role in providing biosimilars to reduce patient costs.
|
$98.55B |
$77.90
-0.33%
|
|
Teva has a growing biosimilars business with launches like SIMLANDI and SELARSDI and an expanding biosimilars pipeline.
|
$22.95B |
$20.01
+0.05%
|
|
The company is advancing a biosimilars business with abatacept, denosumab, and pembrolizumab collaborations, a key growth driver.
|
$11.96B |
$14.34
+1.63%
|
|
Viatris engages in biosimilars alongside generics as part of its complex product strategy.
|
$11.17B |
$9.52
-0.42%
|
|
Biosimilars development and planned launches accompany the generic franchise as a major growth vector.
|
$3.12B |
$9.97
-3.11%
|
|
Organon's Hadlima, Renflexis, and Ontruzant biosimilars are core revenue drivers.
|
$2.75B |
$10.65
+0.80%
|
|
The company markets and commercializes ophthalmic biosimilars (BYOOVIZ and OPUVIZ) as part of its portfolio.
|
$1.38B |
$37.48
-8.02%
|
|
Biosimilars: Amphastar's pipeline includes AMP-004 (insulin aspart) and AMP-028, positioning the company in the biosimilars category.
|
$1.11B |
$23.63
-5.52%
|
|
Kamada maintains a biosimilar portfolio in Israel with planned launches, representing a direct revenue stream.
|
$390.86M |
$6.80
-2.72%
|
|
ROLVEDON competes in the biologics realm (G-CSF) where biosimilar competition is a key dynamic, aligning with Biosimilars as a thematic category.
|
$79.98M |
$0.83
-4.47%
|
|
SCN-106 is described as a potential biosimilar based on Cathflo Activase, indicating a biosimilars program.
|
$9.20M |
$0.70
-6.52%
|
|
NIOPEG is a biosimilar, indicating involvement in biosimilar product development and commercialization.
|
$7.06M |
$1.55
-6.63%
|
Loading industry metrics...
Loading comparison data...
